Xiang Li

Prof. Xiang Li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
QWQiang Wang
Qiang Wang
JXJunnan Xu
Junnan Xu
XLXiaoli Li
Xiaoli Li
ZLZhijia Liu
Zhijia Liu
YHYong Han
Yong Han
XLXiang Li
Xiang Li

7 June 2019 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
JXJunnan Xu
Junnan Xu
LXLiang Xu
Liang Xu
XWXing Wei
Xing Wei
XLXiang Li
Xiang Li
MCMing Cai
Ming Cai
Tacrolimus has been widely used for immunosuppressive therapy in solid organ transplantation (SOT) and allo-geneic stem cell transplantation (allo-SCT) over the past 2 decades. Pancreatitis caused by tacrolimus was rarely reported in kidney transplantation previously. Here we presented a case of a 45-year-old male who underwent kidney transplantation and received immunosuppressive therapy of tacrolimus, on day + 67 after transplantation he developed acute pancreatitis with extremely high blood concentration of tacrolimus. We excluded other possible causes and speculated tacrolimus was the probable inducer of pancreatitis. After tacrolimus was discontinued and alternated with cyclosporine, he gradually recovered and was discharged home with no relapse. Tacrolimus can be a probable cause of pancreatitis after kidney transplantation. We recommended clinicians to be aware of the possibility of tacrolimus-induced pancreatitis during tacrolimus treatment.

5 November 2019 in RSC Advances
Verified
Journal Article
Open access
PDF file
JXJunnan Xu
Junnan Xu
QYQing Yuan
Qing Yuan
KWKang Wu
Kang Wu
XLXiubin Li
Xiubin Li
YZYuanyu Zhao
Yuanyu Zhao
XLXiang Li
Xiang Li
Diabetic nephropathy (DN) is one of the most common microvascular diabetes complications and has become a threat to human health. Bailing capsules (BLCs), containing fermentation products of Cordyceps sinensis, have been commonly used for treatment of renal dysfunction, such as DN. However, mechanisms underlying the protective effects of BLC remain largely obscure and await more investigation. In this study, UPLC-MS-based comprehensive metabolomics along with pattern recognition was applied to explore the urine metabolic alteration of DN as well as therapeutic mechanisms of BLC. Nineteen differentially expressed endogenous metabolites were identified related to DN, which were involved in the perturbations of tyrosine metabolism, tryptophan metabolism, glycine metabolism, purine metabolism, glutamine metabolism, phenylalanine metabolism, histidine metabolism and TCA cycle metabolism pathways. After drug intervention, most of the biomarkers exhibited a certain extent towards normal levels (P < 0.05), which indicated that BLC was an effective drug for treating DN and might play its therapeutic role by retrieving abnormal metabolism pathways. The data obtained in this research may pave the way for further exploration of DN and provide key clues to understand the protective effect of BLC.